[Diffusion of co-tetroxazin into prostatic tissue (author's transl)].
For 2,4-diamino-5-[3,5-dimethoxy-4-(2-methoxyethoxy)]-benzylipyrimidine (tetroxoprim, TXP) and 4-amino-N-(2-pyrimidinyl)benzenesulfonamide (sulfadiazine, SDZ) tissue levels in prostate adenoma patients were 10.75 +/- 5.83 micrograms/g an 8.52 +/- 3.88 micrograms/g, respectively. In accordance with the determined plasma levels of 1.54 +/- 0.53 micrograms/ml TXP and 17.39 +/- 6.11 micrograms/ml SDZ, the prostate/plasma coefficients were found to be 8.26 (TXP) and 0.48 (SDZ).
D004058:Diffusion; D004338:Drug Combinations / Q000378:metabolism; D006801:Humans; D008297:Male; D011467:Prostate / Q000378:metabolism*; D011470:Prostatic Hyperplasia / Q000378:metabolism; D011743:Pyrimidines / Q000378:metabolism*; D013411:Sulfadiazine / Q000378:metabolism*
D004338:Drug Combinations; D011743:Pyrimidines; D013411:Sulfadiazine; C026860:sulfadiazine, tetroxoprim drug combination
Zur Diffusion von Co-tetroxazin in das Prostatagewebe.